

RESEARCH

Open Access

# Spatial and temporal pattern of changes in the number of GAD65-immunoreactive inhibitory terminals in the rat superficial dorsal horn following peripheral nerve injury

Louis-Etienne Lorenzo<sup>1,2,3</sup>, Claire Magnussen<sup>1,2</sup>, Andrea L Bailey<sup>1,2</sup>, Manon St Louis<sup>1</sup>, Yves De Koninck<sup>1,2,3</sup> and Alfredo Ribeiro-da-Silva<sup>1,2,4\*</sup>

## Abstract

Inhibitory interneurons are an important component of dorsal horn circuitry where they serve to modulate spinal nociception. There is now considerable evidence indicating that reduced inhibition in the spinal dorsal horn contributes to neuropathic pain. A loss of these inhibitory neurons after nerve injury is one of the mechanisms being proposed to account for reduced inhibition; however, this remains controversial. This is in part because previous studies have focused on global measurements of inhibitory neurons without assessing the number of inhibitory synapses. To address this, we conducted a quantitative analysis of the spatial and temporal changes in the number of inhibitory terminals, as detected by glutamic acid decarboxylase 65 (GAD65) immunoreactivity, in the superficial dorsal horn of the spinal cord following a chronic constriction injury (CCI) to the sciatic nerve in rats. Isolectin B4 (IB4) labelling was used to define the location within the dorsal horn directly affected by the injury to the peripheral nerve. The density of GAD65 inhibitory terminals was reduced in lamina I (LI) and lamina II (LII) of the spinal cord after injury. The loss of GAD65 terminals was greatest in LII with the highest drop occurring around 3–4 weeks and a partial recovery by 56 days. The time course of changes in the number of GAD65 terminals correlated well with both the loss of IB4 labeling and with the altered thresholds to mechanical and thermal stimuli. Our detailed analysis of GAD65+ inhibitory terminals clearly revealed that nerve injury induced a transient loss of GAD65 immunoreactive terminals and suggests a potential involvement for these alterations in the development and amelioration of pain behaviour.

**Keywords:** Pain, Inhibition, Chronic constriction injury, Neuropathic, IB4, GAD65, Non-peptidergic C fibre, Inhibitory interneurons, Synaptic boutons

## Introduction

Neuropathic pain is a debilitating condition that arises as a “direct consequence of a lesion or disease affecting the somatosensory system” [1]. Nerve injury is accompanied by many alterations in the dorsal horn of the spinal cord which play a role in driving and maintaining the accompanying pain. One such alteration that remains controversial is the

question of whether or not inhibitory interneurons in the dorsal horn are lost in conditions of pain [2,3]. This is an important question to resolve, as these inhibitory interneurons play an important role in modulating sensory information before it is forwarded to higher brain centers.

Most pain related information is forwarded from the periphery to the central nervous system by unmyelinated primary afferents (C fibres) called nociceptors. They have been divided into two roughly distinct populations based on neurochemical and anatomical criteria: the peptidergic and non-peptidergic C fibres [4-7]. Of particular interest to this study are the non-peptidergic C fibres which bind the isolectin B4 (IB4), express purinergic P<sub>2</sub>X<sub>3</sub> receptors

\* Correspondence: [alfredo.ribeirodasilva@mcgill.ca](mailto:alfredo.ribeirodasilva@mcgill.ca)

<sup>1</sup>Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, Quebec H3G 1Y6, Canada

<sup>2</sup>Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec H3A 2B2, Canada

Full list of author information is available at the end of the article

and possess fluoride-resistant acid phosphatase activity [6]. These non-peptidergic fibres terminate primarily in inner lamina II (LII) of the dorsal horn in complex synaptic glomeruli, where they represent the central element and are often postsynaptic to inhibitory interneurons [8-10]. After peripheral injury of the sciatic nerve, IB4-binding is lost and subsequently restored in both the dorsal root ganglia [11] and in the spinal cord [12-15]. The loss of IB4 binding in the dorsal horn corresponds to a bona fide loss of the central terminals of non-peptidergic fibres, as confirmed by electron microscopy (EM) [13], indicating the reliability of this marker.

Inhibitory interneurons represent an important component of dorsal horn circuitry, and form close associations with non-peptidergic fibres. The inhibitory neurotransmitter  $\gamma$ -aminobutyric acid (GABA) is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD), and both neurotransmitter and enzyme are found in these inhibitory interneurons. Two distinct isoforms of GAD exist; GAD 67 and GAD 65 and each is encoded for by a different gene, *gad1* and *gad2*, respectively [16]. In the brain, whereas GAD67 is a cytosolic enzyme that is widely distributed throughout the neuron and often labels cell bodies, GAD65 predominantly localizes to the nerve terminal [17,18]. This differential pattern of staining does not seem to be true in the spinal cord where most axon terminals contain both isoforms [19]. This said, the predominance of each isoform is suggested to vary based on laminar location, with LI and LII containing significantly more inhibitory profiles that largely express GAD65 than deeper laminae, where GAD67 staining is stronger [19]. Recently, GAD65 was shown to be directly implicated in pain mechanisms, as GAD65 knockout mice show impaired synaptic inhibition and sensitized pain behaviour [20].

Neuronal apoptosis in the dorsal horn has been reported in models of neuropathic pain, and it has been suggested that inhibitory interneurons are among the neurons lost [3,21-24]. As mentioned, this loss of dorsal horn inhibitory neurons remains controversial as others propose that it is primarily microglia [25] and not inhibitory neurons that undergo apoptosis [2,25,26]. Regardless of whether or not there is a loss of neurons, remaining inhibitory neurons could either compensate by increasing their number of synaptic profiles or conversely, could shrink by reducing their synaptic connectivity. One way of clarifying the effect of nerve injury on inhibitory neurons in the dorsal horn is to perform a proper quantification of inhibitory terminals. Accordingly, this study was designed to investigate if the number of GAD65-immunoreactive (IR) boutons was altered following a chronic constriction injury (CCI) by means of a polyethylene cuff in rat. IB4 labelling was used as a tool to define the area of the spinal dorsal horn where the afferents affected by the nerve


injury terminate and allowed us to quantify the number of GAD65-IR boutons within the area of lesion of IB4 fibres in lamina II (LII) and in adjacent lamina I (LI). Pain-related behaviour was assessed concomitantly with changes in synaptic terminal density. While some studies have examined global changes in GAD expression throughout the spinal cord [3,22,27], this is the first to demonstrate changes in the number of GAD65-IR boutons, in the region of loss of nociceptive primary afferents at different time points post nerve injury.

## Results

### Behaviour

All of the rats that had undergone cuff surgery exhibited alterations in ipsilateral hind paw posture. Cuff, but not sham animals, held their affected paw in an everted position with the toes plantar-flexed, and avoided bearing weight on it. To facilitate a direct comparison of nociceptive behaviour between sham and cuff animals, all behavioural assessments were normalized to sham controls, with statistics performed on absolute values. Following cuff surgery, animals showed a progressive reduction in paw withdrawal threshold to mechanical stimuli. Test results for mechanical sensitivity are shown in Figure 1A. Ipsilateral to injury, paw withdrawal thresholds (as measured by 50% von Frey withdrawal threshold), decreased starting the 5<sup>th</sup> day post cuff application, and were significantly different from sham ipsilateral thresholds by 14 days. Mechanical sensitivity reached its maximum 21 days post cuff application when mechanical thresholds were only  $16.3 \pm 2.6\%$  of sham ipsilateral values. Gradually, thresholds returned to sham levels by 56 days. Cuff contralateral and sham contralateral withdrawal thresholds were not significantly different at any of the time points tested, demonstrating a lack of bilateral hypersensitivity to mechanical stimuli (data not shown).

In addition to changes in mechanical thresholds, animals showed a decrease in withdrawal latencies to a noxious thermal stimulus. Test results for thermal hyperalgesia, measured using the Hargreaves method, are shown in Figure 1B. Starting 5 days after surgery, withdrawal latencies of the ipsilateral hindpaw declined steadily, and were significantly different when compared to sham ipsilateral control values at 21 days. Heat hyperalgesia was maximal at 28 days, when thermal thresholds were only  $70.1 \pm 4.6\%$  of sham ipsilateral values. Like mechanical hyperalgesia, thermal hyperalgesia was still present at day 42 post-surgery and returned only to sham levels by 56 days. Withdrawal latencies decreased slightly contralateral to injury, but were significantly different from cuff ipsilateral values at day 21 post-surgery. Cuff contralateral and sham contralateral withdrawal thresholds were not significantly different at any of the time points tested (data not shown).




**Figure 1 Behavioural changes following application of the cuff.** Results for the ipsilateral hindpaws are shown for both neuropathic (n = 10) and sham-operated (n = 10) Wistar rats while the contralateral values are shown for neuropathic rats only. Each point represents the mean  $\pm$  SEM as a percentage of sham values (percentage of sham ipsilateral hindpaw for neuropathic ipsilateral results and percentage of sham contralateral hindpaw for neuropathic contralateral results). **A)** 50% withdrawal threshold to von Frey hairs in neuropathic and sham-operated rats as a percentage of sham values obtained with the up-down method. **B)** Assessment of thermal hyperalgesia using the Hargreaves' test. Withdrawal threshold to light stimulus as a percentage of sham values. In **A** and **B**, comparison to sham ipsilateral hindpaw \*P < 0.05, \*\*P < 0.01 by 2 way ANOVA with Bonferroni correction. Comparison to contralateral hindpaw of cuff animals #P < 0.05, ##P < 0.01.

#### IB4 and GAD labelling in Sham and Cuff Animals

To investigate the changes in GAD65-IR inhibitory terminals in the superficial dorsal horn, a double labelling was performed at various time points after cuff application using a monoclonal antibody directed against GAD65 combined with IB4 conjugated to a fluorochrome. The IB4 labelling was used as a tool to define the location of the lesion that occurs in the dorsal horn after CCI. In this

way, the changes in GAD65-IR inhibitory terminals could be quantified in the region where the majority of IB4 fibres terminate, LII, and outside this region, in LI. Morphological studies were performed at 5, 7, 10, 14, 21, 42 and 56 days, allowing us to study the onset of changes, as we had many early time points, and allowed us to discriminate a time at which markers returned to near normal using the 2 later time points. Figure 2 shows representative




images of GAD65 and IB4 labelling in sham (low magnification 2A-D, high magnification 2a-d) and cuff animals (low magnification 2E-H, high magnification 2e-h) 5, 7, 10 and 14 days after surgery, while images taken at days 21, 42 and 56 are shown in Figure 3 (sham 3A-C, 3a-c; cuff 3D-F, 3d-f). Panels labelled with lowercase italic letters (Figure 2a-h and Figure 3a-f) show representative images of the high magnification regions in both lamina I and II that were used for quantification. In these images, GAD65 terminals in red and IB4 terminals in green are most clearly visible.

In sham-operated animals, IB4-binding was mostly restricted to LII, with much less labelling in lamina I. Labelling was particularly intense in LIIi (Figures 2A-D and 3A-C).

At greater magnification, IB4 binding was seen to be concentrated in varicosities (Figures 2a-d and 3a-c). Cell bodies were not labelled. Contrary to IB4 labelling, GAD65 immunoreactivity was observed throughout the entire dorsal horn and its punctate appearance was evident at high magnification (Figures 2a-d and 3a-c). Although some of the structures we name as varicosities certainly represent GABAergic presynaptic dendrites [9], they cannot be distinguished from GABAergic axonal varicosities by light microscopy. All punctate GAD65-IR structures larger than  $0.05\mu\text{m}^2$  were counted, to avoid as much as possible counting cut axons as varicosities or terminals.


Beginning as soon as 5 days post-surgery, cuff animals exhibited a decrease in IB4-labelled (IB4+) varicosities



(compared to sham) ipsilateral to injury. The region of loss of IB4 binding ("lesion" zone, delineated with a yellow rectangle) was most evident in the middle of LII, or more precisely in the intermediate third of the mediolateral extent of the dorsal horn (Figure 2H), which corresponds to the spinal cord projection of the sciatic nerve [28]. The density of IB4+ terminals in this region of LII was quantified over time in cuff and sham animals and the results are displayed in Figure 4A. Values for the ipsi- and contralateral paws have been normalized to those from sham controls, while statistical analysis was performed using absolute values. Ipsilateral to injury, the density of IB4+ terminals in LII was significantly decreased at all time points studied when compared to sham controls and to the side contralateral to injury. From 5 days, the number of IB4+ profiles progressively declined and reached a minimum at 21 days (Figure 3D), when the IB4+ varicosity density ipsilateral to injury was  $1.5 \pm 0.3\%$  of sham controls. Gradually over the next 5 weeks, the density of IB4+ terminals increased; however, an area of depletion was still present at 56 days (Figure 3F) when the density of IB4+ terminals reached only  $52.1 \pm 14.2\%$  of sham controls.

The density of GAD65-IR terminals in LII is displayed in Figure 4B. Cuff application decreased the density of GAD65-IR terminals ipsilateral to injury. While there was a small decrease in the density of GAD65-IR terminals at 5 and 7 days after CCI, it was only at 10 days that the number of GAD65-IR terminals was significantly reduced within the area of IB4+ depletion in LII, when compared with sham controls and to the side contralateral to injury. As seen with IB4, a maximum reduction in GAD65-IR terminals occurred at 21 days, where the density reached  $34.1 \pm 8.5\%$  of sham controls. While a statistical recovery of GAD65 terminals occurred at 42 days when compared to controls, at 56 days a small, albeit significant reduction in the number of GAD65-IR varicosities was still present as density was  $72 \pm 4.5\%$  of sham levels.

The density of GAD65-IR terminals was also quantified in LI (Figure 4C), a region which is much less innervated by non-peptidergic fibres [10,29,30]. From 5 days, the number of GAD65-IR varicosities progressively declined and reached a minimum at 21 days, when their density ipsilateral to injury was  $63.1 \pm 7.7\%$  of sham controls. The reduction in GAD65-IR terminals in LI ( $63.1 \pm 7.7\%$ ) was



**Figure 4** Quantitative analysis of the number of boutons in the superficial dorsal horn of the spinal cord in sham and neuropathic rats at various times after surgery.

Quantification of terminal density was performed within the region of loss of IB4 staining. The number of ipsilateral profiles is shown for neuropathic and sham rats, with contralateral values shown only for neuropathic animals. Each point represents the mean  $\pm$  SEM as a percentage of sham values. **A)** Quantitative analysis of the density of IB4-labelled terminals in lamina II in sham and neuropathic rats. Neuropathic rats had a drastic reduction in the number of IB4+ terminals ipsilateral to injury with maximal loss occurring at 21 days followed by a gradual recovery with numbers remaining significantly different from sham at 42, 56 days. There were always significantly fewer IB4+ terminals ipsilateral vs. contralateral to injury. **B)** Quantitative analysis of GAD65-IR terminals in lamina II in sham and neuropathic rats. Neuropathic rats had a progressive reduction in the number of GAD65-IR terminals ipsilateral to injury with significantly fewer profiles than sham at 10 days, and a maximal loss at 21 days. Despite a partial recovery, GAD65-IR terminals remained significantly reduced at 56 days compared to sham, and at 10, 14, 21, and 56 days were significantly lower than contralateral values. **C)** Quantitative analysis of GAD65-IR terminals in lamina I in sham and neuropathic rats. Neuropathic rats had a small but progressive reduction in the number of GAD65-IR terminals ipsilateral to injury with values significantly different from sham at 10, 14 and 21 days and recovery by 42 days. There was a similar loss of GAD65-IR terminals ipsilateral and contralateral to injury. \* $P < 0.05$ , \*\* $P < 0.01$  sham ipsilateral vs. neuropathic ipsilateral # $P < 0.05$  neuropathic ipsilateral vs. contralateral.

much less pronounced than in LII. Contralateral to injury, a similar though much less marked trend was observed, as the density of GAD65-IR terminals in LI was not significantly different between ipsilateral and contralateral sides at days 5, 7, 10, 14, 21, and 56 days.

A non-parametric Spearman correlation was performed to determine if there is a relationship between the loss of IB4+ terminals and the loss of GAD65+ varicosities in LII. To do this, IB4+ bouton mean density was correlated to their corresponding GAD65+ bouton mean density value in every animal. Interestingly, in the density decreasing phase of both entities, the density of IB4+ terminals was significantly correlated with the density of GAD65-IR terminals from 5 to 14 days along the four time points studied (5, 7, 10, 14 day;  $r = -0.4$ ,  $p = 0.048$ ,  $n = 25$ ). As IB4 terminal density decreased, so did GAD65 density; however, this correlation was not observed in the "recovery phase" of the two markers (from day 21 to 56;  $r = 0.09$ ,  $p = 0.73$ ,  $n = 16$ ).

## Discussion

In this study, the time-dependant changes in the number of GAD65-IR inhibitory terminals were examined in the superficial dorsal horn of the rat spinal cord following polyethylene cuff induced CCI of the sciatic nerve. Using specific markers, and restrictive quantification techniques, we show conclusively that cuff application results in a significant but transient loss of GAD65 immunoreactivity,

corresponding to inhibitory terminals, within the area of loss of IB4+ boutons in LII and, dorsal to it, in LI. The early time-course of the loss of GAD65-IR terminals correlated well with the loss of IB4+ terminals in LII. Furthermore, the pattern of alterations in terminal densities paralleled the changes in thresholds to both mechanical and thermal stimuli.

It is well known that loss of GABAergic or glycinergic inhibition in the dorsal horn leads to allodynia in naive rats [31], and that loss of inhibitory tone in the dorsal horn might underlie symptoms of neuropathic pain [32]. In light of these results, many studies have explored the mechanisms which might contribute to this altered neurotransmission. Of particular interest was the question of whether or not nerve injury resulted in a loss of inhibitory interneurons. Conflicting evidence quickly emerged. Some studies suggested that GABAergic interneurons were lost after nerve injury as indicated by a loss of GABA immunoreactivity in the dorsal horn [23,24,27] and the presence of apoptotic markers [3,21,22] while other studies using stereological counts opposed these results by showing that neurons in LI-III were not lost after either CCI [2,26] or spared nerve injury (SNI) [25]. Independent of a change in the number of GABAergic cells following injury, it is likely that they either retract or extend their distal processes, a phenomenon that has been well described in hippocampal neurons after stress [33].

In this study, GAD65 was used to visualize inhibitory terminals by immunofluorescence and to clarify the effect of nerve injury on inhibitory neurons in the dorsal horn. GAD65 was chosen for a number of reasons. 1. It primarily localizes to nerve terminals [17-19]. 2. In laminae I and II, where this study was focused, inhibitory profiles with high levels of GAD65 are relatively common; this is not the case in more ventral laminae where profiles with high levels of GAD67 dominate [19]. 3. GAD65 knockout mice have impaired GABA synaptic function and a lower baseline pain threshold indicating a direct role for this isoform in both inhibition and pain [20]. Using software parameters that specifically allowed puncta the size of GABAergic boutons with a minimal staining intensity to be counted as inhibitory terminals, we have clearly shown that the density of GAD65+ inhibitory terminals was reduced in the ipsilateral superficial dorsal horn of the spinal cord after cuff injury. The loss of GAD65-IR inhibitory terminals was not constant over time or space. The loss of inhibitory terminals was most significantly reduced at 3–4 weeks and recovered partially by 56 days. Furthermore, the loss of GAD65-IR terminals was greatest in LII, the region where the majority of IB4+ fibres terminate and are lost after nerve injury.

The finding that GAD65-IR density is temporally altered by nerve injury is consistent with a number of

complementary findings. Meisner et al. [22] showed that GAD65/67 immunoreactivity in the dorsal horn is reduced at 8 weeks after spinal cord injury (SCI), as are the protein levels of GAD67 and GAD65 at 6 weeks. Moore et al. [3] showed using Western blot that GAD65 protein is transiently reduced in the ipsilateral dorsal horn by CCI and SNI; however, unlike us, they saw a full restoration of GAD65 levels at 4 weeks post CCI. These immunoblotting approaches used only provide a global assessment of GAD protein levels in the entire ipsilateral dorsal horn and likely do not reflect what is happening in LI and LII, regions important in nociceptive transmission. Finally, Eaton et al. [27] show that GAD67-IR cell bodies in LI-III initially decrease in number 3 days post CCI but begin to increase, eventually surpassing levels in intact animals at 8 weeks after nerve injury. The different time-course seen in this study is most likely attributable to the fact that cell bodies, rather than terminals, were counted. The major advantage of our study over the previous studies is that we were able to specifically quantify the number of inhibitory terminals at various time points, within the specific area in the spinal dorsal horn where the afferents affected by the nerve injury terminate.

It is possible that the loss of GAD65 immunoreactivity does not necessarily reflect a loss of inhibitory terminals, but instead simply a down regulation of the protein. Because it has been shown that some boutons in the superficial dorsal horn express high levels of GAD65 and low levels of GAD67 [19], it is possible that these boutons would be unable to synthesize GABA after GAD65 down-regulation, effectively rendering these synapses non-functional (as far as GABAergic transmission is concerned). One limitation of the current study is that we investigate the changes in GAD65 immunoreactivity only, and do not consider GAD67. While some studies suggest that GAD65 is more dramatically reduced [3], others report that GAD65 and 67 are similarly decreased by nerve injury [22]. If GAD67 is unchanged or even up regulated, some inhibitory synapses could remain functional. Contrary to this, the frequency of inhibitory postsynaptic currents (mIPSCs) is reduced by CCI [3] and in GAD65 knockout animals [20], indicating that inhibitory neurons release less GABA in these models. To more globally assess the entire GABAergic inhibitory terminal population in neuropathic pain, antibodies against GAD67 could be used in combination with those against GAD65 or even by using antibodies that indiscriminately recognize both isoforms. Alternatively, the vesicular GABA transporter (VGAT), which acts as an anatomical marker for inhibitory terminals [34,35], could be used.

One of the most interesting and relevant findings of this study is that the behavioural results matched well with the loss and recovery of both IB4+ and GAD65-IR terminals. As the density of both IB4+ fibre terminals and GAD65-

IR inhibitory terminals decreased from 5–21 days, sensitivity to both mechanical and thermal stimuli increased. As GABAergic inhibitory terminals are known to be pre-synaptic to the central boutons of type Ia glomeruli [9,36], it is hypothesized that the GAD65-IR terminals might retract and become lost after glomerular IB4+ central terminals undergo degenerative atrophy. This is supported by the fact that we found that loss of GAD65-IR terminals was significantly correlated with the loss of IB4+ terminals in LII from 5–14 days after cuff placement. Between 14 and 28 days, a time at which both IB4+ and GAD65-IR terminals were maximally depleted, hypersensitivities were greatest. It is possible that the disrupted synaptic organization in the dorsal horn at this time might drive the development of neuropathic pain. In normal animals, nociceptive information is forwarded to the spinal cord via two distinct populations of C fibres: the peptidergic and non-peptidergic. Evidence suggests that nerve injury produces more profound and longer lasting changes to both the central and peripheral terminals of non-peptidergic C fibres in comparison to the peptidergic population, which appears to be more resilient [13,37–39]. We suggest that nociceptive information following nerve injury might be preferentially transmitted through the less affected peptidergic population. Given that peptidergic afferents do not receive axo- or dendroaxonic synapses from GABAergic neurons and therefore undergo less direct inhibition [8], it is conceivable that nociceptive signals are more easily transmitted from these remaining peptidergic fibres to projection neurons. It might be argued as well that as the loss of IB4+ terminals and of GAD65-IR is parallel, the loss of inhibition would be on terminals that disappeared with the lesion. However, such reasoning would assume that the major synaptic targets of GAD65-IR boutons in LII are the central boutons of Type Ia synaptic glomeruli, which is far from the truth. Indeed, it should be kept in mind that the great majority of GABA- and glycine-containing terminals are presynaptic to spinal neurons, not to primary afferent terminals [36,40].

In LI, despite the few IB4 fibres that terminate there [30], the loss and recovery of GAD65 terminals followed the same time course as within LII, albeit less severe. These data from LI suggest that it is mostly the inhibitory terminals that contact dorsal horn neurons that are lost after CCI. In this way, the loss of inhibitory terminals could result in impaired dorsal horn inhibition and altered nociception.

Finally, we suggest that the amelioration in behaviour seen at later time points might be in part due to a recovery of the normal synaptic architecture of type Ia glomeruli and the reestablishment of an equilibrium between the peptidergic and non-peptidergic populations. In line with this idea, regenerative proliferation of IB4+ terminals is observed after cuff [13], and 40 days after crush injury

growth cones of primary afferent terminals have been shown to re-establish synapses with dendritic processes from substantia gelatinosa neurons [41]. Future studies using EM would be required to determine if GAD65-IR terminals resume proper connectivity and presynaptic inhibition to non-peptidergic C fibres. Recently it was shown that when immature GABAergic interneurons were transplanted and integrated into spinal cord circuitry, the mechanical hypersensitivity associated with SNI was reversed [42]. These results suggest a potential therapeutic role for restoring normal inhibitory function in the dorsal horn in chronic pain conditions.

## Conclusions

In this study we show conclusively that GAD65 immunoreactivity is transiently lost, suggesting a loss of inhibitory terminals, in the superficial dorsal horn of the rat spinal cord following polyethylene cuff-induced lesion of the sciatic nerve. The reduction of inhibitory terminals was most severe in LII and the time course correlated with both the loss of IB4+ terminals and with the altered thresholds to both mechanical and thermal stimuli. Further studies are required to assess whether or not GABAergic terminals return to their correct location, and re-establish a proper inhibitory synaptic connectivity with IB4+ central terminals. Additionally, future studies should quantify the proportion of lost inhibitory terminals that were in contact with IB4+ terminals versus dorsal horn neurons.

## Methods

In total, 88 male Wistar rats (200–300 g; Charles River Canada) were used in this study. Animals were maintained on a 12:12 hour light: dark cycle and received food and water ad libitum. Experiments were performed during the light cycle. All protocols were approved by the McGill University Animal Care Committee and complied with the guidelines set by the Canadian Council on Animal Care and International Association for the Study of Pain.

## Induction of neuropathic pain

Neuropathic pain was induced using a variation of the Mosconi and Kruger [43] technique. In this model, a unilateral chronic constriction of the sciatic nerve is achieved by placing a single polyethylene cuff of fixed diameter around the nerve [44]. All surgery was done under aseptic conditions. Animals were anaesthetized under 5% isoflurane in O<sub>2</sub> in an induction chamber, and maintained at 2.5% isoflurane throughout the remainder of the surgery. The animals were shaved on their left side below the pelvis. The left common sciatic nerve was exposed via blunt dissection through the biceps femoris muscle. The sciatic nerve was isolated from surrounding fascia using a glass probe, and a 4–6 mm section of the



nerve was elevated to allow for placement of the cuff around the nerve. The cuff consisted of a 2 mm piece of split PE-60 polyethylene tubing with an inner diameter of 0.76 mm (Intramedic PE-60, Intramedic, Fisher Scientific, Canada). The muscle and shaved skin layers were closed separately using 4-0 Vicryl absorbable suture (Ethicon, Johnson & Johnson, New Jersey, USA) and an antibiotic ointment was applied. Sham operated rats served as controls, and underwent the same procedure but did not receive any nerve manipulation. Animals were returned to their home cages and were allowed to recover for 5 days before undergoing behavioural testing.

### Behavioural testing

Behavioural testing was performed on 20 Wistar rats, 10 cuff and 10 sham animals. Each animal was followed throughout the following time points: 5, 7, 10, 14, 21, 28, 42 and 56 post surgery.

### Mechanical Allodynia

Using the up-down method, responses to mechanical stimuli were tested with von Frey filaments of increasing stiffness [45]. Rats were placed in a transparent cage atop a mesh floor and were allowed to acclimatize for 2 days prior to baseline testing for 15 minutes each day. Baseline thresholds were taken 2 days prior to cuff surgery. Von Frey filaments (0.6, 1, 1.4, 2, 4, 6, 8, 10, 15, 26 g) were applied serially in ascending order of strength to the plantar surface of the hindpaw with enough force to elicit a slight bend in the filament. Each filament was applied for 5 seconds or until a flexion reflex occurred. An acute withdrawal of the paw was considered a positive response, and signalled the application of the next weaker filament. In the absence of a paw withdrawal response, termed a negative response, the next stronger stimulus was presented. The resulting pattern of positive and negative responses was tabulated, where X = withdrawal and 0 = no withdrawal. The 50% paw withdrawal threshold (grams) was calculated as  $(10_f^{[X + k\delta]})/10000$  where  $X_f$  = value (in log units) of the final von Frey hair used,  $k$  = value for the pattern of positive/negative responses and  $\delta$  = mean difference in log unit between stimuli (here,  $\delta = 0.224$ ).

### Heat Hyperalgesia

The Hargreaves test, which measures the latency of paw withdrawal from a radiant heat source, was used to assess thermal hyperalgesia [46]. Animals were placed in a transparent plastic cage on top of a glass plate. For 2 days prior to baseline testing, animals were habituated to the apparatus for 15 min each day. On baseline test day, which occurred 2 days prior to cuff surgery, the plantar surface of the hindpaw was exposed to a beam of radiant heat (adjusted to 30% of its maximum) applied through the glass floor. The light beam is controlled by a photo-

cell switch which automatically turns off the light when the rat lifts its limb. This apparatus allows for the measurement of paw withdrawal latency. To prevent tissue damage, a cut-off of 20.48 seconds was used. Testing was performed on both ipsi- and contralateral paws, and measurements reflect the average of 3 trials, conducted at 5 minute intervals.

### Tissue preparation

A separate group of animals was used for immunohistochemistry. At 5, 7, 10, 14, 21, 42 and 56 days post-surgery, rats were deeply anaesthetized with Equithesin and transcardially perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4, for 30 min. For each time point, 3-5 sham and 4-8 cuff animals were used. The spinal cords were removed and post-fixed in 4% PFA for 2 hours and cryoprotected in 30% sucrose in 0.1 M PB overnight. The following day, 35  $\mu$ m transverse sections from the 4<sup>th</sup> and 5<sup>th</sup> lumbar segments (L4 and L5) were cut on a freezing sledge microtome (SM2000R, Leica Microsystems, Ontario, Canada) and collected in phosphate-buffered saline (PBS) containing 0.2% Triton X-100 (PBS-T).

### Double labelling

Double labelling immunofluorescence was performed to explore the changes in GAD65 immunoreactivity both within and outside of the zone of the IB4 lesion that occurs following CCI. Non-specific staining was blocked by pre-treatment for 60 minutes with 10% Normal Donkey Serum (NDS) (Jackson ImmunoResearch, Pennsylvania, USA) diluted in PBS-T. Sections were then treated with a mixture of mouse monoclonal anti-GAD-65 antibody (1:1000, Millipore/Chemicon, Catalog No. MAB351, Lot No. 0510013666) and IB4 conjugated to Alexa Fluor 488 (1:200, Invitrogen/Molecular Probes; Catalog No. I21411, Lot No. 38753A) in 5% NDS in PBS-T, and allowed to incubate overnight at 4°C. On day 2, donkey anti-mouse IgG antibody conjugated to Rhodamine Red X (1:200, Jackson ImmunoResearch, Catalog No. 715-296-150, Lot No. 70290, 73632) was pre-absorbed with 10 mg/ml of acetone rat brain powder (Sigma, USA) in 5% NDS for 30 min at 37°C. This preparation was vortexed every 10 min, followed by centrifugation at 4000 r.p.m for 20 minutes at 4°C. Following washing, sections were incubated for 2 hours in this mixture. Sections were washed in 0.01 M PBS, mounted on gelatin-subbed slides, and coverslipped using Aquapolymount (Polysciences, Pennsylvania, USA).

### Quantification of IB4+ non-peptidergic and GAD65+ inhibitory terminals by image analysis

Sections from sham and cuff animals were examined using a Zeiss LSM 510 confocal scanning laser microscope (Zeiss Canada) equipped with argon and helium-neon lasers. Appropriate filters were selected for the separate

detection of Alexa 488 and Rhodamine Red X using a multi-track scanning method. Twelve-bit images were taken with either a 20X water-immersion or a 63X oil-immersion objective lens. To ensure consistency among samples, all parameters of laser power, pinhole size and image detection were kept unchanged. The chosen parameters were set so that the detection of the staining was maximal while avoiding pixel saturation. For quantification, the channels corresponding to each staining were exported separately as TIFF files. The images were then analyzed with an MCID Elite Image analysis system version 7 (Imaging Research Inc., Ontario, Canada).

Quantitative analysis was performed on 6 tissue sections from each animal. Analysis was performed within the region of loss of IB4 staining which occurs predominantly in LII in the intermediate third of the medial-lateral extent of the dorsal horn. This IB4 lesion is denoted by a yellow box in Figures 2 and 3. To analyze the density of IB4- and GAD65-labelled terminals in the superficial dorsal horn (LI and LII), a rectangle measuring 15 X 40  $\mu\text{m}$  was placed with the longer side at the edge of the white matter for LI, and a rectangle measuring 30 X 50  $\mu\text{m}$  was placed horizontally at 50  $\mu\text{m}$  from the white matter within the region of decreased IB4 staining for each animal. On the contralateral side, these rectangles were placed in a position that mirrored their location on the ipsilateral side. In sham animals, where no IB4 lesion is present, these rectangles were placed where the IB4 lesion normally occurs in neuropathic animals. The number of IR profiles per unit area was calculated by the MCID software. To facilitate the detection of the labelled boutons and to differentiate them from background, we used a function in the software named “target accentuate”, which diminishes the overall contrast of the image but decreases the contrast of smaller structures (e.g. boutons) to a lesser extent than larger structures. In order to compensate for failing to count overlapped varicosities, the software performed a correction based on the average area of each type of varicosity (for IB4 = 0.3  $\mu\text{m}^2$ , for GAD65 bouton = 0.2  $\mu\text{m}^2$ ), to obtain an estimated varicosity count. Overlapping boutons were not frequent with the reduced optical section thickness used. Furthermore, there was no significant difference in average bouton size from sham and lesioned animals. Most importantly, the software was set to eliminate punctae with areas below 0.05  $\mu\text{m}^2$  to ensure that cut axons were not counted as axonal varicosities. We have used this approach in other publications see e.g. [47].

### Statistical analysis

All values are expressed as a percentage of sham controls; however, statistical analysis was performed using absolute values. Ipsilateral hindpaw withdrawal thresholds of sham and cuff animals were analyzed using a 2 way

ANOVA with a Bonferroni post-hoc test. For immunohistochemistry, the numbers of profiles were statistically analyzed using a one way ANOVA t-test to compare sham to cuff animal ipsilateral values. A paired one way ANOVA t-test was used to compare ipsilateral and contralateral values in each cuff animal. To investigate a correlation between IB4 and GAD65 densities, a non-parametric Spearman correlation was performed. Significance was set at  $p < 0.05$ .

### Antibody specificity and controls

In all immunostainings, omission of primary antibodies resulted in negative stainings. The anti-GAD65 monoclonal antibody recognizes the 65 kDa isoform of GAD, and was generated by immunizing mice with purified GAD from rat brain. The mouse anti-GAD65 monoclonal antibody has been well characterized by Chang and Gottlieb where it was shown to specifically recognize rat GAD65 on Western blots [48]. Atkinson et al. showed that this monoclonal antibody stained terminals in the rat central nervous system [49].

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

LEL, ALB, and ARdS designed all experimental protocols of this study. LEL performed most of the animal surgeries, processed some of the material for immunocytochemistry, conducted the animal behaviour testing, performed some of the confocal microscopy analyses and designed all the illustrations. CM and LEL analyzed and interpreted the data and CM wrote the first version of the manuscript. ALB did some of the animal surgeries and processed some of the material for immunocytochemistry. MSL processed some of the animals for immunocytochemistry, obtained images in the confocal microscope and performed most of the image analysis quantification. YDK helped with the interpretation of the data and contributed significantly to the editing of the manuscript. ARdS provided supervision for data analysis, study direction, image acquisition, manuscript design and revisions. All authors have read and approved the final draft of this manuscript.

### Acknowledgements

Supported by Canadian Institute of Health Research (CIHR) grant MOP-79411 to ARS- and MOP-12942 to YDK. YDK was a Chercheur National of the Fonds de la recherche en santé du Québec. LEL was supported by a CIHR Fellowship. CM and AB were the recipients of PhD studentships from the Louise and Alan Edwards Foundation. The authors would like to thank Amy Sur, Tina Scardochio and Jacynthe Laliberté for their technical assistance.

### Author details

<sup>1</sup>Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, Quebec H3G 1Y6, Canada. <sup>2</sup>Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec H3A 2B2, Canada. <sup>3</sup>Institut Universitaire en Santé Mentale de Québec, Québec, QC G1J 2G3, Canada. <sup>4</sup>Departments of Anatomy and Cell Biology, McGill University, Montreal, Quebec H3A 2B2, Canada.

Received: 4 April 2014 Accepted: 26 August 2014

Published: 4 September 2014

### References

1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J: **Neuropathic pain: redefinition and a grading system for clinical and research purposes.** *Neurology* 2008, **70**:1630–1635.

2. Polgar E, Hughes DJ, Riddell JS, Maxwell DJ, Puskar Z, Todd AJ: **Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain.** *Pain* 2003, **104**:229–239.
3. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ: **Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.** *J Neurosci* 2002, **22**:6724–6731.
4. Nagy JJ, Hunt SP: **Fluoride-resistant acid phosphatase-containing neurones in dorsal root ganglia are separate from those containing substance P or somatostatin.** *Neuroscience* 1982, **7**:89–97.
5. Hunt SP, Rossi J: **Peptide- and non-peptide-containing unmyelinated primary afferents: the parallel processing of nociceptive information.** *Philos Trans R Soc Lond B Biol Sci* 1985, **308**:283–289.
6. Alvarez FJ, Fyffe RE: **Nociceptors for the 21st century.** *Curr Rev Pain* 2000, **4**:451–458.
7. Hunt SP, Mantyh PW: **The molecular dynamics of pain control.** *Nat Rev Neurosci* 2001, **2**:83–91.
8. Ribeiro-da-Silva A, DeKoninck Y: **Morphological and neurochemical organization of the spinal dorsal horn.** In *Pain*. Edited by Bushnell MC, Basbaum AI. New York: Academic Press; 2008:279–310.
9. Ribeiro-da-Silva A: **Substantia gelatinosa of the spinal cord.** In *The rat nervous system*. Edited by Paxinos G. San Diego: Elsevier Academic Press; 2004:129–148.
10. Lorenzo LE, Ramien M, Louis MS, De Koninck Y, Ribeiro-da-Silva A: **Postnatal changes in the Rexed lamination and markers of nociceptive afferents in the superficial dorsal horn of the rat.** *J Comp Neurol* 2008, **508**:592–604.
11. Hammond DL, Ackerman L, Holdsworth R, Elzey B: **Effects of spinal nerve ligation on immunohistochemically identified neurons in the L4 and L5 dorsal root ganglia of the rat.** *J Comp Neurol* 2004, **475**:575–589.
12. Molander C, Wang HF, Rivero-Melian C, Grant G: **Early decline and late restoration of spinal cord binding and transganglionic transport of isolectin B4 from *Griffonia simplicifolia* I after peripheral nerve transection or crush.** *Rest Neurol Neurosci* 1996, **10**:123–133.
13. Bailey AL, Ribeiro-da-Silva A: **Transient loss of terminals from non-peptidergic nociceptive fibers in the substantia gelatinosa of spinal cord following chronic constriction injury of the sciatic nerve.** *Neuroscience* 2006, **138**:675–690.
14. Casals-Diaz L, Vivo M, Navarro X: **Nociceptive responses and spinal plastic changes of afferent C-fibers in three neuropathic pain models induced by sciatic nerve injury in the rat.** *Exp Neurol* 2009, **217**:84–95.
15. Raginov IS, Chelyshev YA: **Post-traumatic survival of sensory neurons of different subpopulations.** *Neurosci Behav Physiol* 2005, **35**:17–20.
16. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ: **Two genes encode distinct glutamate decarboxylases.** *Neuron* 1991, **7**:91–100.
17. Kaufman DL, Houser CR, Tobin AJ: **Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions.** *J Neurochem* 1991, **56**:720–723.
18. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR: **Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms.** *J Neurosci* 1994, **14**:1834–1855.
19. Mackie M, Hughes DJ, Maxwell DJ, Tillakaratne NJ, Todd AJ: **Distribution and colocalisation of glutamate decarboxylase isoforms in the rat spinal cord.** *Neuroscience* 2003, **119**:461–472.
20. Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ: **Epigenetic suppression of GAD65 expression mediates persistent pain.** *Nat Med* 2011, **17**:1448–1455.
21. Scholz J, Broom DC, Youn DH, Mills CD, Kohno T, Suter MR, Moore KA, Decosterd I, Coggeshall RE, Woolf CJ: **Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury.** *J Neurosci* 2005, **25**:7317–7323.
22. Meisner JG, Marsh AD, Marsh DR: **Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury.** *J Neurotraum* 2010, **27**:729–737.
23. Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J: **Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts.** *Neuroscience* 1997, **76**:845–858.
24. Castro-Lopes JM, Tavares I, Coimbra A: **GABA decreases in the spinal cord dorsal horn after peripheral neurectomy.** *Brain Res* 1993, **620**:287–291.
25. Polgar E, Hughes DJ, Arham AZ, Todd AJ: **Loss of neurons from laminae I-III of the spinal dorsal horn is not required for development of tactile allodynia in the spared nerve injury model of neuropathic pain.** *J Neurosci* 2005, **25**:6658–6666.
26. Polgar E, Gray S, Riddell JS, Todd AJ: **Lack of evidence for significant neuronal loss in laminae I-III of the spinal dorsal horn of the rat in the chronic constriction injury model.** *Pain* 2004, **111**:144–150.
27. Eaton MJ, Plunkett JA, Karmally S, Martinez MA, Montanez K: **Changes in GAD- and GABA- immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors.** *J Chem Neuroanat* 1998, **16**:57–72.
28. Swett JE, Woolf CJ: **The somatotopic organization of primary afferent terminals in the superficial laminae of the dorsal horn of the rat spinal cord.** *J Comp Neurol* 1985, **231**:66–77.
29. Gerke MB, Plenderleith MB: **Analysis of the distribution of binding sites for the plant lectin *Bandeiraea simplicifolia* I-isolectin B-4 on primary sensory neurones in seven mammalian species.** *Anat Rec* 2002, **268**:105–114.
30. Saeed AW, Ribeiro-da-Silva A: **Non-peptidergic primary afferents are presynaptic to neurokinin-1 receptor immunoreactive lamina I projection neurons in rat spinal cord.** *Mol Pain* 2012, **8**:64.
31. Yaksh TL: **Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition - effects of modulatory receptor systems and excitatory amino-acid antagonists.** *Pain* 1989, **37**:111–123.
32. Sandkuhler J: **The role of inhibition in the generation and amplification of pain.** In *Current Topics in Pain: 12th World Congress on Pain*. Edited by Castro-Lopes J. Seattle: IASP Press; 2008:53–71.
33. McEwen BS: **Stress and hippocampal plasticity.** *Annu Rev Neurosci* 1999, **22**:105–122.
34. Chaudhry FA, Reimer RJ, Bellocchio EE, Danbolt NC, Osen KK, Edwards RH, Storm-Mathisen J: **The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons.** *J Neurosci* 1998, **18**:9733–9750.
35. Polgar E, Todd AJ: **Tactile allodynia can occur in the spared nerve injury model in the rat without selective loss of GABA or GABA(A) receptors from synapses in laminae I-II of the ipsilateral spinal dorsal horn.** *Neuroscience* 2008, **156**:193–202.
36. Lorenzo LE, Godin AG, Wang F, St-Louis M, Carbonetto S, Wiseman PW, Ribeiro-da-Silva A, De Koninck Y: **Gephyrin clusters are absent from small diameter primary afferent terminals despite the presence of GABA<sub>A</sub> receptors.** *J Neurosci* 2014, **34**:8300–8317.
37. Cameron AA, Cliffer KD, Dougherty PM, Garrison CJ, Willis WD, Carlton SM: **Time course of degenerative and regenerative changes in the dorsal horn in a rat model of peripheral neuropathy.** *J Comp Neurol* 1997, **379**:428–442.
38. Peleshok JC, Ribeiro-da-Silva A: **Delayed reinnervation by nonpeptidergic nociceptive afferents of the glabrous skin of the rat hindpaw in a neuropathic pain model.** *J Comp Neurol* 2011, **519**:49–63.
39. Kalous A, Osborne PB, Keast JR: **Acute and chronic changes in dorsal horn innervation by primary afferents and descending supraspinal pathways after spinal cord injury.** *J Comp Neurol* 2007, **504**:238–253.
40. Todd AJ, Spike RC: **The localization of classical transmitters and neuropeptides within neurons in laminae I-III of the mammalian spinal dorsal horn.** *Prog Neurobiol* 1993, **41**:609–645.
41. Csillik B, Knyihar-Csillik E: **Regenerative synaptoneogenesis in the Mammalian spinal cord: dynamics of synaptoneogenesis restoration in the Rolando Substance after transganglionic degenerative atrophy.** *J Neural Transm* 1981, **52**:303–317.
42. Braz JM, Sharif-Naeini R, Vogt D, Kriegstein A, Alvarez-Buylla A, Rubenstein JL, Basbaum AI: **Forebrain GABAergic neuron precursors integrate into adult spinal cord and reduce injury-induced neuropathic pain.** *Neuron* 2012, **74**:663–675.
43. Mosconi T, Kruger L: **Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: Ultrastructural morphometric analysis of axonal alterations.** *Pain* 1996, **64**:37–57.
44. Pitcher GM, Ritchie J, Henry JL: **Nerve constriction in the rat: model of neuropathic, surgical and central pain.** *Pain* 1999, **83**:37–46.
45. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: **Quantitative assessment of tactile allodynia in the rat paw.** *J Neurosci Meth* 1994, **53**:55–63.

46. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: **A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.** *Pain* 1988, **32**:77–88.
47. Majdi M, Ribeiro-da-Silva A, Cuello AC: **Cognitive impairment and transmitter-specific pre- and postsynaptic changes in the rat cerebral cortex during ageing.** *Eur J Neurosci* 2007, **26**:3583–3596.
48. Chang YC, Gottlieb DI: **Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase.** *J Neurosci* 1988, **8**:2123–2130.
49. Atkinson L, Batten TF, Moores TS, Varoqui H, Erickson JD, Deuchars J: **Differential co-localisation of the P2X7 receptor subunit with vesicular glutamate transporters VGLUT1 and VGLUT2 in rat CNS.** *Neuroscience* 2004, **123**:761–768.

doi:10.1186/1744-8069-10-57

**Cite this article as:** Lorenzo *et al.*: Spatial and temporal pattern of changes in the number of GAD65-immunoreactive inhibitory terminals in the rat superficial dorsal horn following peripheral nerve injury. *Molecular Pain* 2014 **10**:57.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

